Van - is that public knowledge? I'll try a Google, but any chance of a link please?
"In monkeys necropsied 24 hours after the final dose of adipotide, lesions associated with the kidney were observed and were found to be dose-dependent; such lesions were not present in the control group (Fig. 7A). The observed lesions were scored minimal to mild in the low-dose group, minimal to mild in most of the middle-dose monkeys, and minimal to moderate in the high-dose group. The primary lesions were classified as degenerative/necrotic (single-cell necrosis) and reactive/regenerative (Fig. 7B). In monkeys necropsied at the end of the recovery period, minimal tubular degeneration with few degenerate cells was observed in one monkey in the middle-dose group and in two monkeys in the high-dose group. Tubular regeneration and tubular necrosis (single cell with few necrotic cells) were minimal in all monkeys after recovery (Fig. 7C). Thus, the primary side effect of adipotide is relatively mild, predictable, and reversible renal injury and altered tubular function. Abnormal lipid accumulation (including hepatic steatosis) was not noted in any of the monkeys that received adipotide."
"Whereas a detailed mechanism of action for adipotide treatment remains to be fully elucidated, we observed that weight loss in obese rhesus monkeys occurred concurrently with a reduction in food intake. Strikingly, lean rhesus monkeys receiving a therapeutic dose of adipotide did not lose weight (fig. S5). This finding suggests that the mechanism of action may be obesity-specific in primates."
The big monkey study -
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666164/ . It's interesting reading.
